Glenmark Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹3,901Cr
- +15.1% YoY
- −35.5% QoQ
- Net profit
- ₹403Cr
- +15.8% YoY
- −33.9% QoQ
- Margin
- 22%
- +4 pp YoY
- −17 pp QoQ
Glenmark Pharmaceuticals Ltd Q3 FY26 key numbers
- Revenue
- FY '28 expected to exceed $50 million collectively from new assets excluding RYALTRIS.
As stated in Glenmark Pharmaceuticals Ltd's Q3 FY26 earnings call transcript · published 3 Jul 2026. Reported figures, not investment advice.
The short version
TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17). FY '28 is expected to see significant growth driven by launches of innovative assets including Aumolertinib and Hengrui products.
From Glenmark Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17).
- FY '28 expected to exceed $50 million collectively from new assets excluding RYALTRIS (Page 17).
- India market growing strong at 19% vs market growth of 10-11%; expected to remain strong for 3-5 years with oncology and chronic respiratory driving growth (Page 17).
- Europe business anticipated to grow at high single to low double digits in coming years, aided by new respiratory product launches like RYALTRIS and WINLEVI (Page 10).
- Next 5 years’ growth driven by 7-8 innovative assets including Aumolertinib, Hengrui assets, RYALTRIS, WINLEVI, TEVIMBRA, BRUKINSA (Page 9).
2 more points from Glenmark Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Glenmark Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned capex for the next fiscal year is around INR 700-800 crores annually.
- Investments primarily go into:
- Ongoing capex on plants and expanding current manufacturing lines and facilities.
- Strategic in-licensing products such as the Hengrui asset.
- No current in-house biologic manufacturing; biologics manufacturing is outsourced, but future developments unknown.
- Capex mix: approximately 55% intangible assets (e.g., licensing, product acquisition) and 45% tangible assets (e.g., plant expansion).
2 more points from Glenmark Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Glenmark Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Glenmark Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Glenmark Pharmaceuticals Ltd — Quarterly revenue & net profit
Glenmark Pharmaceuticals Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 3,901 | 3,388 | +15.1% | 6,047 | -35.5% |
| Operating profit (EBITDA) | 870 | 600 | +45% | 2,360 | -63.1% |
| Operating margin | 22% | 18% | +4 pp | 39% | -17 pp |
| Profit before tax | 534 | 456 | +17.1% | 967 | -44.8% |
| Net profit (PAT) | 403 | 348 | +15.8% | 610 | -33.9% |
| EPS (₹) | 14.29 | 12.33 | +15.9% | 21.63 | -33.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.2K Cr, net profit ₹264 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glenmark Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Glenmark Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Glenmark Pharmaceuticals Ltd Q3 FY26 results?
TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17). FY '28 is expected to see significant growth driven by launches of innovative assets including Aumolertinib and Hengrui products.
What is Glenmark Pharmaceuticals Ltd share price analysis?
Glenmark Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹63,749 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glenmark Pharmaceuticals Ltd planning capital expenditure?
Planned capex for the next fiscal year is around INR 700-800 crores annually.
Keep Glenmark Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
